India’s effort to eliminate tuberculosis depends on a chain of interventions that begins with identifying people who may have the disease and continues through diagnosis, treatment, follow-up and prevention. Screening is an important first step, but it must connect people to appropriate testing and care if it is to reduce the burden of TB.
A government backgrounder released on October 13, 2026, reported that cumulative screenings under the intensified TB Mukt Bharat Abhiyaan had crossed 28.1 crore. It also reported that more than 20 lakh individuals had received TB Preventive Treatment, 5.7 lakh new Ni-kshay Mitras had joined the initiative, and 46,118 Gram Panchayats had received TB-free certification.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: India’s ongoing TB elimination effort and the expansion of screening, treatment and community support.
Location: Nationwide, across India.
Authority/Organisation: Ministry of Health and Family Welfare and the National Tuberculosis Elimination Programme.
Action Taken: The government reported more than 28.1 crore cumulative screenings, over 20 lakh people provided TB Preventive Treatment, 5.7 lakh new Ni-kshay Mitras and 46,118 Gram Panchayats awarded TB-free certification.
Impact: Expanded screening and community participation may help identify cases earlier and improve access to support. The long-term impact depends on diagnostic confirmation, appropriate treatment, follow-up and sustained prevention.
The same backgrounder said India’s yearly emerging TB cases declined by 21% between 2015 and 2024, compared with a 12% decline globally over the same period. It also reported treatment coverage of 92% for India against 78% globally.
These figures describe progress reported by the government, but they represent different measures. Screening counts indicate the reach of testing and identification activities; treatment coverage measures how much of the estimated burden is reached by treatment services; and changes in incidence reflect the estimated rate of new cases. None of these measures, individually, means that transmission has stopped or that every person with TB has been diagnosed.
Why early detection matters
Editorial Analysis
Why This Matters
TB elimination is not achieved through screening alone. People who may have the disease must be connected to diagnostic services, and those diagnosed need appropriate treatment and follow-up. Accessible healthcare, preventive services for eligible people and community support can help reduce delays and barriers to care. Clear information also helps counter stigma and misconceptions that may prevent people from seeking help.
Tuberculosis is an infectious disease caused by bacteria. It most commonly affects the lungs, although it can also affect other parts of the body.
Symptoms of pulmonary TB can include a persistent cough, chest pain, breathlessness and blood in sputum. Other possible symptoms include unexplained weight loss, fatigue and fever. Symptoms vary according to the part of the body affected, and some can overlap with other illnesses.
A person with a persistent cough lasting two weeks or more, or other symptoms that raise concern about TB, should seek assessment at a health facility. Symptoms alone cannot confirm the disease, and a person should not self-diagnose or begin anti-TB medicines without clinical evaluation.
Early assessment matters because undiagnosed disease can delay treatment and allow transmission to continue in some circumstances. Screening programmes are intended to help identify people who may otherwise not reach diagnostic services promptly, particularly in communities where access to healthcare is limited.
Screening is not the same as diagnosis
Screening helps identify people who may need further assessment. A screening result is not necessarily a confirmed TB diagnosis.
Depending on the symptoms, clinical assessment and type of suspected disease, health professionals may use sputum testing, rapid molecular tests, chest X-rays or other investigations. The appropriate combination depends on the individual case and applicable clinical guidance.
Molecular tests can help detect TB bacteria and, in some cases, identify resistance to particular medicines. Drug-resistance testing is important because the treatment required for drug-resistant TB can differ from the regimen used for drug-sensitive disease.
India’s programme has expanded the use of handheld X-ray equipment to help screen people in communities and settings where access to diagnostic facilities may be difficult. The October 13 government backgrounder reported a 34-fold increase in X-ray screening through handheld units.
An increase in screening capacity can help find people who need further evaluation. Its eventual public-health value depends on what follows: timely diagnostic confirmation, appropriate treatment, contact assessment where indicated and continued monitoring.
Why completing treatment matters
TB is treatable, but successful treatment requires the prescribed medicines to be taken according to the healthcare provider’s instructions for the full recommended course. Stopping treatment early, missing doses or changing medicines without medical advice can jeopardise treatment outcomes.
The duration and combination of medicines depend on factors such as the type of TB, drug susceptibility, clinical circumstances and the treatment regimen selected. Drug-resistant TB may require a different combination of medicines and a specialised treatment plan.
The government’s October 13 backgrounder highlighted the introduction of a shorter BPaLM regimen for eligible patients with drug-resistant TB. BPaLM stands for bedaquiline, pretomanid, linezolid and moxifloxacin. This is not a universal regimen for everyone with TB: eligibility and treatment decisions must be determined by qualified healthcare professionals under current programme guidelines.
Follow-up is also important. Healthcare teams may monitor symptoms, treatment response, adverse effects and test results. Patients experiencing side effects should contact their treatment provider rather than stopping or altering medicines independently.
Preventive treatment and household contacts
TB preventive treatment is different from the treatment used for active disease. It is intended for eligible people who may be at risk of developing active TB, following appropriate evaluation and clinical guidance.
People who live with someone diagnosed with infectious pulmonary TB may be advised to undergo assessment. Healthcare workers can determine whether contacts require further testing, evaluation for active disease or preventive treatment.
The decision is not automatic for every contact. Age, medical history, other health conditions and the possibility of active TB can affect the next steps. Active disease must be appropriately evaluated before preventive treatment is started.
Expanding preventive services can help reduce the likelihood that eligible people progress to active disease. It works alongside, rather than replaces, early diagnosis and effective treatment for people who already have TB.
Community participation and Ni-kshay Mitras
India’s TB response also involves community organisations and individual supporters. Ni-kshay Mitras are participants in the programme’s support initiative, which encourages contributions to the nutritional and broader needs of people undergoing TB treatment.
The government backgrounder published on October 13 reported that 5.7 lakh new Ni-kshay Mitras had joined the initiative. Community involvement can help patients navigate services, access support and feel less isolated during treatment.
The programme also reported 46,118 Gram Panchayats receiving TB-free certification. Such recognition should be understood within the programme’s certification framework; it does not mean that the risk of TB has permanently disappeared from those communities.
Community participation is particularly relevant because stigma can discourage people from seeking testing, disclosing symptoms or continuing care. Respectful communication and protection of patients’ dignity can make it easier for people to access health services.
What AI and digital tools can—and cannot—do
The government’s October 13 backgrounder also highlighted the TB Mukt Bharat App and its AI chatbot, Khushi, alongside AI-driven triage tools.
Digital tools can support public awareness, help users navigate information and assist healthcare systems in prioritising further assessment. Their effectiveness depends on the quality of the information, accessibility, appropriate oversight and integration with health services.
An AI tool should not be treated as a substitute for medical diagnosis. A chatbot cannot independently confirm whether someone has TB, determine the right medicines or replace clinical assessment and laboratory testing.
The purpose of these tools is to support the wider health system. People with possible symptoms still need appropriate evaluation, and patients receiving treatment need care from qualified providers.
Where people can seek help
India’s Central Tuberculosis Division provides information about the National Tuberculosis Elimination Programme, diagnosis, treatment and patient support.
The government states that TB diagnostic and treatment services are available free of cost through government health facilities and designated treatment centres. People can contact the national TB helpline, Nikshay Sampark, on 1800-11-6666 for information and assistance.
People seeking care should explain their symptoms and any relevant history to a healthcare professional. Anyone already receiving treatment should continue to follow their prescribed plan and contact their provider if they experience difficulties or side effects.
India’s TB elimination effort will ultimately be judged not only by how many people are screened, but by whether those who need care are diagnosed promptly, receive appropriate treatment, complete it successfully and have access to support without stigma.
